IE45539B1 - Immunogenic product of tetanus toxin - Google Patents
Immunogenic product of tetanus toxinInfo
- Publication number
- IE45539B1 IE45539B1 IE1590/77A IE159077A IE45539B1 IE 45539 B1 IE45539 B1 IE 45539B1 IE 1590/77 A IE1590/77 A IE 1590/77A IE 159077 A IE159077 A IE 159077A IE 45539 B1 IE45539 B1 IE 45539B1
- Authority
- IE
- Ireland
- Prior art keywords
- substance
- fragment
- vaccine
- tetanus toxin
- tetanus
- Prior art date
Links
- 108010055044 Tetanus Toxin Proteins 0.000 title claims abstract description 32
- 229940118376 tetanus toxin Drugs 0.000 title claims abstract description 32
- 230000002163 immunogen Effects 0.000 title claims abstract description 12
- 239000012634 fragment Substances 0.000 claims abstract description 51
- 108091005804 Peptidases Proteins 0.000 claims abstract description 16
- 102000035195 Peptidases Human genes 0.000 claims abstract description 16
- 235000019833 protease Nutrition 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 41
- 230000008569 process Effects 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
- 108090000526 Papain Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 229940055729 papain Drugs 0.000 claims description 9
- 235000019834 papain Nutrition 0.000 claims description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 206010043376 Tetanus Diseases 0.000 claims description 5
- 150000001299 aldehydes Chemical class 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 238000001962 electrophoresis Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 4
- 238000001502 gel electrophoresis Methods 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 4
- 230000036647 reaction Effects 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229960005367 tetanus antitoxin Drugs 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 229960002766 tetanus vaccines Drugs 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000203 mixture Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000003217 Tetany Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2634584A DE2634584C3 (de) | 1976-07-31 | 1976-07-31 | Atoxisches, immunogenes Produkt aus Tetanus-Toxin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE45539L IE45539L (en) | 1978-01-31 |
| IE45539B1 true IE45539B1 (en) | 1982-09-22 |
Family
ID=5984461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1590/77A IE45539B1 (en) | 1976-07-31 | 1977-07-29 | Immunogenic product of tetanus toxin |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS5326319A (fr) |
| AT (1) | AT362498B (fr) |
| AU (1) | AU516191B2 (fr) |
| BE (1) | BE857373A (fr) |
| CA (1) | CA1099635A (fr) |
| DE (1) | DE2634584C3 (fr) |
| DK (1) | DK342577A (fr) |
| EG (1) | EG12732A (fr) |
| FI (1) | FI58500C (fr) |
| FR (1) | FR2360315A1 (fr) |
| GB (1) | GB1570958A (fr) |
| IE (1) | IE45539B1 (fr) |
| IL (1) | IL52617A (fr) |
| IT (1) | IT1085660B (fr) |
| LU (1) | LU77874A1 (fr) |
| NL (1) | NL7708279A (fr) |
| NO (1) | NO772704L (fr) |
| SE (1) | SE7708693L (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516442D0 (en) * | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
-
1976
- 1976-07-31 DE DE2634584A patent/DE2634584C3/de not_active Expired
-
1977
- 1977-07-26 NL NL7708279A patent/NL7708279A/xx not_active Application Discontinuation
- 1977-07-27 EG EG446/77A patent/EG12732A/xx active
- 1977-07-27 AU AU27380/77A patent/AU516191B2/en not_active Expired
- 1977-07-28 FI FI772305A patent/FI58500C/fi not_active IP Right Cessation
- 1977-07-28 SE SE7708693A patent/SE7708693L/ not_active Application Discontinuation
- 1977-07-29 GB GB31968/77A patent/GB1570958A/en not_active Expired
- 1977-07-29 IE IE1590/77A patent/IE45539B1/en unknown
- 1977-07-29 DK DK342577A patent/DK342577A/da not_active Application Discontinuation
- 1977-07-29 JP JP9213677A patent/JPS5326319A/ja active Pending
- 1977-07-29 IL IL52617A patent/IL52617A/xx unknown
- 1977-07-29 NO NO772704A patent/NO772704L/no unknown
- 1977-07-29 LU LU77874A patent/LU77874A1/xx unknown
- 1977-07-29 CA CA283,802A patent/CA1099635A/fr not_active Expired
- 1977-07-29 AT AT563477A patent/AT362498B/de not_active IP Right Cessation
- 1977-07-29 IT IT26354/77A patent/IT1085660B/it active
- 1977-08-01 FR FR7723600A patent/FR2360315A1/fr active Granted
- 1977-08-01 BE BE179821A patent/BE857373A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI58500C (fi) | 1981-02-10 |
| FR2360315B1 (fr) | 1980-04-11 |
| DE2634584B2 (de) | 1979-03-22 |
| DK342577A (da) | 1978-02-01 |
| DE2634584C3 (de) | 1979-11-08 |
| GB1570958A (en) | 1980-07-09 |
| JPS5326319A (en) | 1978-03-11 |
| AU516191B2 (en) | 1981-05-21 |
| IL52617A0 (en) | 1977-10-31 |
| EG12732A (en) | 1979-09-30 |
| IE45539L (en) | 1978-01-31 |
| NL7708279A (nl) | 1978-02-02 |
| FI772305A (fr) | 1978-02-01 |
| SE7708693L (sv) | 1978-02-01 |
| DE2634584A1 (de) | 1978-02-02 |
| BE857373A (fr) | 1978-02-01 |
| IT1085660B (it) | 1985-05-28 |
| NO772704L (no) | 1978-02-01 |
| CA1099635A (fr) | 1981-04-21 |
| LU77874A1 (fr) | 1978-02-02 |
| FI58500B (fi) | 1980-10-31 |
| AU2738077A (en) | 1979-02-01 |
| IL52617A (en) | 1980-12-31 |
| ATA563477A (de) | 1980-10-15 |
| AT362498B (de) | 1981-05-25 |
| FR2360315A1 (fr) | 1978-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diaz et al. | Bullous pemphigoid antigen: isolation from normal human skin | |
| US4704274A (en) | Method for the purification of LPF-HA | |
| US5840700A (en) | Methods of producing transfer factor | |
| US5667787A (en) | Purification of a pertussis outer membrane protein | |
| JP2009173945A (ja) | Ｇｂｓトキシン／ｃｍ１０１の精製方法 | |
| CS244906B2 (en) | Production method of antigen agent for limitation or prevention of tooth defects | |
| Cunningham et al. | Peptic Digestion of Streptococcal M Protein I. Effect of Digestion at Suboptimal pH upon the Biological and Immunochemical Properties of Purified M Protein Extracts | |
| US5989542A (en) | Capsular polysaccharides from enterococci | |
| HU217582B (hu) | Streptococcus B csoportba tartozó törzsek elleni immunitást biztosító, Rib fehérjenevű felületi protein, eljárás a protein tisztítására, reagenskészlet és gyógyszerkészítmény | |
| JPH03191789A (ja) | 百日咳菌からの６９０００ダルトンの抗原性タンパク質の精製方法 | |
| Slutzky et al. | Leishmanial excreted factor: protein-bound and free forms from promastigote cultures of Leishmania tropica and Leishmania donovani | |
| EP0175841B1 (fr) | Méthode de production d'un composant de vaccin contre la coqueluche et vaccin combiné d'antigène de coqueluche, de toxoide de la diphtérie et de toxoide du tétanos | |
| KR100266556B1 (ko) | 백일해균의 방어성분의 분리방법 | |
| IE42760B1 (en) | Derivatives of the tetanus toxin, process for their preparation and agents containing them | |
| US4200627A (en) | Atoxic, immunogenic product of tetanus toxin | |
| IE45539B1 (en) | Immunogenic product of tetanus toxin | |
| Lindahl et al. | Binding to erythrocyte membrane glycoproteins and carbohydrate specificity of F41 fimbriae of enterotoxigenic Escherichia coli | |
| Pier et al. | Extracellular antigens of Nocardia asteroides: I. Production and immunologic characterization | |
| Rogers et al. | Immunological and chemical studies on sub-fractions of carcinoembryonic antigen | |
| US3968202A (en) | Tetanus antigen and process for its manufacture | |
| Nicolet et al. | Farmer's lung: immunological response to a group of extracellular enzymes of Micropolyspora faeni. An experimental and field study. | |
| Ferreira et al. | Mouse C4 (Ss): three-step purification of its C4c fragment and production of a monospecific antiserum | |
| WO1991018104A1 (fr) | Compositions de l'enzyme indh et leurs procedes d'utilisation | |
| Matheson et al. | Serologic relationships between β-lysins of different species | |
| Gordon et al. | Immunogenicity of solubilized tumor antigen extracted from P1798 murine lymphoma cells or isolated from tumor‐bearer ascites fluid and reactivity with anti‐thy‐1.2 antiserum |